Table V.

Maximum Acceptable 10-Year Serious-Adverse-Event Risk for Selected Treatment Benefits

	Patients			Parents
Treatment Benefit	MAR	90% Confidence Interval		MAR	90% Confidence Interval
Risk of PML
Severe to remission	7.00	6.18	7.82	8.26	5.51	11.01
Severe to mild	6.11	5.40	6.82	6.31	3.93	8.69
Severe to moderate	1.94	1.21	2.67	5.21	2.86	7.56
Moderate to remission	3.95	2.92	4.98	3.62	1.95	5.29
Moderate to mild	2.21	1.54	2.88	1.04	0.18	1.90
Risk of serious infection
Severe to remission	7.35	6.74	7.96	7.11	4.91	9.31
Severe to mild	6.70	6.18	7.22	5.61	3.51	7.71
Severe to moderate	2.78	0.58	4.98	4.59	2.30	6.88
Moderate to remission	5.47	4.94	6.00	2.99	1.35	4.63
Moderate to mild	3.70	1.98	5.42	0.50	−0.14	1.14
Risk of lymphoma
Severe to remission	8.18	7.33	9.03	8.93	4.30	13.56
Severe to mild	7.26	6.53	7.99	5.56	1.90	9.22
Severe to moderate	3.89	2.75	5.03	3.69	0.70	6.68
Moderate to remission	5.51	4.90	6.12	1.95	0.67	3.24
Moderate to mild	4.21	3.40	5.02	1.02	0.64	1.40